Literature DB >> 18177995

Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist.

Jennifer E Mersereau1, Nitzan Levy, Richard E Staub, Scott Baggett, Tatjana Zogovic, Tetjana Zogric, Sylvia Chow, William A Ricke, Mary Tagliaferri, Isaac Cohen, Leonard F Bjeldanes, Dale C Leitman.   

Abstract

After the Women's Health Initiative found that the risks of hormone therapy outweighed the benefits, a need for alternative drugs to treat menopausal symptoms has emerged. We explored the possibility that botanical agents used in Traditional Chinese Medicine for menopausal symptoms contain ERbeta-selective estrogens. We previously reported that an extract containing 22 herbs, MF101 has ERbeta-selective properties. In this study we isolated liquiritigenin, the most active estrogenic compound from the root of Glycyrrhizae uralensis Fisch, which is one of the plants found in MF101. Liquiritigenin activated multiple ER regulatory elements and native target genes with ERbeta but not ERalpha. The ERbeta-selectivity of liquiritigenin was due to the selective recruitment of the coactivator steroid receptor coactivator-2 to target genes. In a mouse xenograph model, liquiritigenin did not stimulate uterine size or tumorigenesis of MCF-7 breast cancer cells. Our results demonstrate that some plants contain highly selective estrogens for ERbeta.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18177995      PMCID: PMC2277338          DOI: 10.1016/j.mce.2007.11.020

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  41 in total

1.  Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens.

Authors:  J An; C Tzagarakis-Foster; T C Scharschmidt; N Lomri; D C Leitman
Journal:  J Biol Chem       Date:  2001-02-21       Impact factor: 5.157

2.  Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators.

Authors:  J An; R C Ribeiro; P Webb; J A Gustafsson; P J Kushner; J D Baxter; D C Leitman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

3.  Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.

Authors:  C L Loprinzi; J W Kugler; J A Sloan; J A Mailliard; B I LaVasseur; D L Barton; P J Novotny; S R Dakhil; K Rodger; T A Rummans; B J Christensen
Journal:  Lancet       Date:  2000-12-16       Impact factor: 79.321

4.  Estrogenic and antiproliferative activities of isoliquiritigenin in MCF7 breast cancer cells.

Authors:  Marcello Maggiolini; Giancarlo Statti; Adele Vivacqua; Sabrina Gabriele; Vittoria Rago; Monica Loizzo; Francesco Menichini; Sebastiano Amdò
Journal:  J Steroid Biochem Mol Biol       Date:  2002-11       Impact factor: 4.292

5.  Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.

Authors:  Sylvia Wassertheil-Smoller; Susan L Hendrix; Marian Limacher; Gerardo Heiss; Charles Kooperberg; Alison Baird; Theodore Kotchen; J David Curb; Henry Black; Jacques E Rossouw; Aaron Aragaki; Monika Safford; Evan Stein; Somchai Laowattana; W Jerry Mysiw
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

6.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Authors:  Sally A Shumaker; Claudine Legault; Stephen R Rapp; Leon Thal; Robert B Wallace; Judith K Ockene; Susan L Hendrix; Beverly N Jones; Annlouise R Assaf; Rebecca D Jackson; Jane Morley Kotchen; Sylvia Wassertheil-Smoller; Jean Wactawski-Wende
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

7.  Pilot evaluation of gabapentin for treating hot flashes.

Authors:  L Loprinzi; Debra L Barton; Jeff A Sloan; Katherine M Zahasky; De Anne R Smith; Sandhya Pruthi; Paul J Novotny; Edith A Perez; Bradley J Christensen
Journal:  Mayo Clin Proc       Date:  2002-11       Impact factor: 7.616

8.  A novel method for growing human breast epithelium in vivo using mouse and human mammary fibroblasts.

Authors:  Hema Parmar; Peter Young; Joanne T Emerman; Richard M Neve; Shanaz Dairkee; Gerald R Cunha
Journal:  Endocrinology       Date:  2002-12       Impact factor: 4.736

9.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

10.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

Authors:  Rowan T Chlebowski; Susan L Hendrix; Robert D Langer; Marcia L Stefanick; Margery Gass; Dorothy Lane; Rebecca J Rodabough; Mary Ann Gilligan; Michele G Cyr; Cynthia A Thomson; Janardan Khandekar; Helen Petrovitch; Anne McTiernan
Journal:  JAMA       Date:  2003-06-25       Impact factor: 56.272

View more
  69 in total

1.  Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.

Authors:  Lonnele J Ball; Nitzan Levy; Xiaoyue Zhao; Chandi Griffin; Mary Tagliaferri; Isaac Cohen; William A Ricke; Terence P Speed; Gary L Firestone; Dale C Leitman
Journal:  Mol Cell Endocrinol       Date:  2008-11-18       Impact factor: 4.102

2.  The effects of the botanical estrogen, isoliquiritigenin on delayed spatial alternation.

Authors:  Payel Kundu; Steven L Neese; Suren Bandara; Supida Monaikul; William G Helferich; Daniel R Doerge; Ikhlas A Khan; Susan L Schantz
Journal:  Neurotoxicol Teratol       Date:  2018-02-03       Impact factor: 3.763

Review 3.  Development of subtype-selective oestrogen receptor-based therapeutics.

Authors:  Stefan Nilsson; Konrad F Koehler; Jan-Åke Gustafsson
Journal:  Nat Rev Drug Discov       Date:  2011-09-16       Impact factor: 84.694

4.  Therapeutic significance of estrogen receptor β agonists in gliomas.

Authors:  Gangadhara R Sareddy; Binoj C Nair; Vijay K Gonugunta; Quan-guang Zhang; Andrew Brenner; Darrell W Brann; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Mol Cancer Ther       Date:  2012-03-21       Impact factor: 6.261

5.  Chiral analytical method development of liquiritigenin with application to a pharmacokinetic study.

Authors:  Casey L Sayre; Mandi Hopkins; Jody K Takemoto; Neal M Davies
Journal:  Biomed Chromatogr       Date:  2012-07-20       Impact factor: 1.902

6.  Dynamic residual complexity of the isoliquiritigenin-liquiritigenin interconversion during bioassay.

Authors:  Charlotte Simmler; Atieh Hajirahimkhan; David C Lankin; Judy L Bolton; Tristesse Jones; Djaja D Soejarto; Shao-Nong Chen; Guido F Pauli
Journal:  J Agric Food Chem       Date:  2013-02-22       Impact factor: 5.279

7.  Evidence for Chemopreventive and Resilience Activity of Licorice: Glycyrrhiza Glabra and G. Inflata Extracts Modulate Estrogen Metabolism in ACI Rats.

Authors:  Shuai Wang; Tareisha L Dunlap; Lingyi Huang; Yang Liu; Charlotte Simmler; Daniel D Lantvit; Jenna Crosby; Caitlin E Howell; Huali Dong; Shao-Nong Chen; Guido F Pauli; Richard B van Breemen; Birgit M Dietz; Judy L Bolton
Journal:  Cancer Prev Res (Phila)       Date:  2018-10-04

Review 8.  Cancer therapy using natural ligands that target estrogen receptor beta.

Authors:  Gangadhara R Sareddy; Ratna K Vadlamudi
Journal:  Chin J Nat Med       Date:  2015-11

9.  Estrogen receptor beta-selective agonists stimulate calcium oscillations in human and mouse embryonic stem cell-derived neurons.

Authors:  Lili Zhang; Brigitte E Blackman; Marcus D Schonemann; Tatjana Zogovic-Kapsalis; Xiaoyu Pan; Mary Tagliaferri; Heather A Harris; Isaac Cohen; Renee A Reijo Pera; Synthia H Mellon; Richard I Weiner; Dale C Leitman
Journal:  PLoS One       Date:  2010-07-27       Impact factor: 3.240

10.  Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists.

Authors:  Sreenivasan Paruthiyil; Aleksandra Cvoro; Xiaoyue Zhao; Zhijin Wu; Yunxia Sui; Richard E Staub; Scott Baggett; Candice B Herber; Chandi Griffin; Mary Tagliaferri; Heather A Harris; Isaac Cohen; Leonard F Bjeldanes; Terence P Speed; Fred Schaufele; Dale C Leitman
Journal:  PLoS One       Date:  2009-07-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.